PART ONE

From Plant Medicine to Alkaloid Products

The story of kratom in America is usually told as a story about a plant. It would be more accurate to tell it as a story about a process — the quiet, systematic transformation of a botanical substance into something the original plant would barely recognize. But to understand that process, you have to understand the longer history it interrupted. Kratom did not arrive into a pharmacological vacuum. It arrived into a civilization that had spent a century deliberately forgetting what plants could do — and had then built the tools to extract, concentrate, and sell what it had forgotten. That transformation is the foundation of what this series calls retail pharmacology.

The Alkaloid Foundation

Plants have been producing biologically active compounds throughout recorded history and long before it — a vast chemical library shaped by the pressures that drive adaptation in living systems. The results are remarkable. Morphine from the opium poppy. Quinine from the bark of the cinchona tree. Caffeine from coffee and tea. Nicotine from tobacco. Cocaine from the coca leaf. Atropine from belladonna. The list of molecules that have shaped human history, medicine, and consciousness reads like a botanical catalog.

For most of recorded history, the relationship between humans and plant chemistry was direct and practical. Physicians worked with tinctures — alcohol-based extracts that preserved and concentrated plant compounds without isolating them. A pharmacist’s preparation varied with the season, the soil, the harvest. The medicine was alive in the way that all botanical things are alive: variable, contextual, inseparable from its source.

Kratom fit comfortably within this tradition. The Mitragyna speciosa tree, a member of the coffee family native to Thailand, Malaysia, and Indonesia, produces leaves containing dozens of alkaloids. Two dominate the pharmacological profile: mitragynine, present in significant quantities and producing mild stimulant effects at lower doses with opioid-like properties at higher doses, and 7-hydroxymitragynine, which occurs naturally in much smaller concentrations but interacts with mu-opioid receptors with considerable potency. For generations, laborers in Southeast Asia chewed the leaves fresh or brewed them into tea. The preparation was simple. The pharmacology was governed entirely by what the plant produced. Nobody was engineering anything. Understanding how dramatically that changed — and what it means for people using modern extract products — is central to the 7-OH vs. kratom. comparison.

From Field to Laboratory

For most of human history, the drugs that shaped civilization came from the ground. They were grown, harvested, and prepared by hand — in fields and gardens, by farmers and apothecaries, through processes that were local, variable, and impossible to standardize at scale. The opium poppy was cultivated across Asia and the Middle East. Cinchona bark was harvested from South American forests. Coca leaves were grown and chewed in the Andes. The pharmacological supply chain ran through agriculture, and the people who controlled it were growers, traders, and the physicians who prepared what arrived at their doors.

The isolation of morphine from opium in the early nineteenth century was a landmark event not just in chemistry but in the history of commerce: for the first time, the active compound in a plant could be separated from the plant itself, concentrated, measured, and produced at scale. The field was no longer the source. The laboratory was. And the laboratory could do things the field never could — produce a consistent product, dose it precisely, manufacture it in quantities no harvest could match, and — crucially — own it through patents in ways no farmer’s crop ever could.

The economics of this transition were as transformative as the chemistry. A tincture prepared from variable plant material could not be patented. A novel isolated or synthesized compound could. The financial architecture of the modern pharmaceutical industry was built on that distinction, and it pointed the entire direction of medicine away from the botanical and toward the synthetic — away from the field and toward the laboratory, away from the variable preparation and toward the standardized dose.

How Western Medicine Forgot the Plants

The early twentieth century brought a transformation in Western medicine so complete that it reshaped not just how diseases were treated but what medicine believed itself to be. The Flexner Report of 1910, funded in significant part by the Rockefeller and Carnegie Foundations, evaluated medical schools across the United States and Canada and recommended sweeping consolidation around laboratory science, standardized training, and pharmaceutical pharmacology. Schools teaching botanical and homeopathic traditions — many of them with deep roots in the agrarian pharmacological tradition — closed within a decade.

The institutional logic was partly scientific and partly economic. Purified compounds and synthetic pharmaceuticals offered something botanical preparations could never reliably provide: consistency. Once a molecule could be isolated or synthesized, it could be produced with identical chemical structure across millions of doses, manufactured in centralized facilities, and distributed through regulated supply chains. Industrial medicine could scale in ways that the apothecary’s garden never could. And in an era defined by industrial scale, that difference was decisive.

The result was that an entire pharmacological tradition — centuries of accumulated knowledge about plant chemistry and its interactions with human physiology — was effectively sidelined within a generation. Plants like kratom continued to be used in their regions of origin but existed outside Western medical frameworks for most of the twentieth century. There was no institutional structure to study them, regulate them, or integrate them. When they eventually re-entered Western markets, they arrived without the clinical infrastructure that had accompanied every other pharmacologically significant substance.

The Return of Botanical Pharmacology

Kratom began appearing in Western markets in the early 2000s, initially through online vendors importing dried leaf powder. These early products were not dramatically different from traditional preparations. The alkaloid profile was roughly intact, and the substance occupied an ambiguous regulatory space: not a controlled drug, not an approved medicine, technically a botanical supplement in a category that existing frameworks had never anticipated.

The re-emergence of kratom was part of a broader return of botanical pharmacology through the back door of consumer retail — the very door that institutional medicine had spent a century trying to close. Cannabis legalization brought plant-derived psychoactive products into regulated retail markets. Scientific research into psilocybin for depression and PTSD began rehabilitating the pharmacological credibility of plant compounds that had been scheduled out of medical use for decades. In each case the pattern was the same: a biologically active compound with deep roots in the agrarian pharmacological tradition, pushed to the margins by twentieth-century institutional medicine, finding its way back through channels the institutions had not been built to govern.

What had changed was that the laboratory revolution had produced extraction and concentration technologies that could now be applied to the returning botanical compounds. The plants came back. But they came back through the laboratory. And what the laboratory produced, the retail infrastructure was ready to distribute.

The Four-Stage Model: How Retail Pharmacology Works

Kratom’s evolution from traditional leaf preparation to modern alkaloid product is not an isolated phenomenon. It follows a pattern visible across pharmacologically active consumer products — a four-stage process by which biologically active compounds are transformed from natural substances into engineered consumer products distributed through retail markets rather than medical systems.

Understanding this process is more important than understanding any single product, because the products change while the process continues. The following framework describes how retail pharmacology develops — and why markets consistently select for the same characteristics at each stage.

Stage 1 — Discovery

A biologically active compound exists in nature, typically with a long history of traditional or regional use.

Examples: Kratom leaf, tobacco, coca leaf, psilocybin mushrooms, caffeine, cannabis

Stage 2 — Extraction & Concentration

Technology allows active compounds to be isolated and concentrated, dramatically increasing potency relative to the natural source.

Examples: Kratom extracts and 7-OH isolates, nicotine salts, cocaine from coca, high-caffeine concentrates

Stage 3 — Product Engineering

Concentrated compounds are formulated into consumer products designed for convenience, consistency, and noticeable effect. Delivery format is optimized for the target market.

Examples: Kratom shots and tablets, vape devices, energy drinks, cannabis edibles and tinctures

Stage 4 — Retail Distribution

Engineered products reach consumers directly through retail markets rather than traditional medical channels, without physician involvement.

Examples: Smoke shops, convenience stores, dispensaries, online marketplaces, direct-to-consumer apps

Across these four stages, markets tend to reward products that produce faster onset, stronger signals, and more repeatable reinforcement cycles. This is not a conspiracy or an intentional design choice by any single actor. It is a selection pressure. Products with these characteristics spread more efficiently, generate more repeat consumption, and outcompete products that deliver slower, more diffuse signals. The market selects for compression the way natural selection favors adaptive traits — not through intention but through outcome. This dynamic — the systematic narrowing of the time between dose and relief — is what the framework calls interval compression.

The unit of analysis in retail pharmacology is therefore not the plant. It is the product system: plant plus extraction plus formulation plus distribution plus behavioral design. Two products both labeled “kratom” can deliver pharmacological experiences with almost nothing in common — one a mild botanical stimulant, the other a concentrated opioid agonist sold without a prescription at a gas station. Understanding why requires understanding the system that produced them, not just the substance they share a name with.

I have spent more than twenty years working on the front lines of addiction recovery — in leadership and intake roles, and in the spaces where trajectory is set. I watched people arrive with a withdrawal profile that, in its essential features, looked like compressed-cycle-opioid-dependence — from taking what they thought was a harmless plant supplement. The gap between what the label said and what the product actually was is not a labeling problem. It is a systems problem. And it is the predictable output of the four-stage process described above. If you’re trying to understand where your current use falls on that spectrum, the How the Kinetic Exit Works is a good place to start.

Next: Part Two — The Expansion of Modern Drug Markets

Back to Series Overview Retail Pharmacology

John Leonard is the founder of Pivot Protocols and a recovery program leader with 23 years of front-line experience. The frameworks on this site were developed through direct observation, pattern recognition, and grounding in published pharmacological research. He is not a clinician or medical provider.